Barcelona, Spain, September 4, 2018 – Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of its GamaSTAN® immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis. GamaSTAN® is now available to healthcare providers across the country.
GamaSTAN® is the only immune globulin product on the U.S. market
SEPTEMBER 5, 2018